PAI-1, an important component of the hemostasis system, is a specific inhibitor of both urokinase type and tissue type plasminogen activators. PAI-1 belongs to the serpin family. The interaction between somatomedin-like domain of vitronectin and PAI-1 leads to stabilization of the latter. PAI-1 latency transition is related to the conformational changes in the reactive central loop. The inhibitory mechanism of PAI-1 is in accordance with the classic scheme of serpin action. PAI-1 blocks the adhesion mediated by UPA and integrins, so this inhibitor plays an important role in adhesion process and angiogenesis. An altered PAI-1 level is associated with the development of cardiovascular diseases, kidney fibrosis, diabetes, cancerogenesis.

Keywords: PAI-1, fibrinolysis, cell migration.
Characteristics of PAI proteins

<table>
<thead>
<tr>
<th>Name</th>
<th>Concentration in human plasma</th>
<th>Molecular mass, kDa</th>
<th>The constant inhibition (M⁻¹c⁻¹) toward</th>
</tr>
</thead>
<tbody>
<tr>
<td>PAI-1</td>
<td>In average 24 ng/ml</td>
<td>52</td>
<td>10⁻⁶</td>
</tr>
<tr>
<td>PAI-2</td>
<td>Negligible under normal state. At pregnancy 100 – 300 ng/ml</td>
<td>60</td>
<td>9×10⁻⁵</td>
</tr>
<tr>
<td>PAI-3</td>
<td>2–5 µg/ml</td>
<td>57</td>
<td>8×10⁻³</td>
</tr>
</tbody>
</table>

Fig. 1. Primary structure of human PAI-1 (All numbers of amino acid residues correspond to the protein premature form). N-glycosylated Asn [25]; MQMSPALTCLVLGLAVFEGSA or MQMSPALTCLVLGLAVFEGEG is a peptide bond [23, 24]; FRLFFLRF and EVERARFIINDWKTHTIK are sites of vitronectin binding [35, 36]; R‘M is a peptide bond, which is cleaved by TPA or UPA; PEEIMDR is a site of TPA or UPA binding.

Among these proteins PAI-1 is the most interesting, because this inhibitor has structural peculiarities, which help it to interact with the components of extracellular matrix and therefore its functional role is more complicated [12, 13].

The average concentration of PAI-1 in human plasma is 24 ng/ml, but it can fluctuate from 6 to 85 ng/ml. The PAI-1 concentration is 2-3 times more in arterial blood than in venous one [14, 15]. Besides, the concentration of this inhibitor is changing during the day: it is higher before noon than in the afternoon [11]. According to a modern version, the pool of PAI-1 is formed from several sources: platelets, hepatocytes, endothelial cells, macrophages, and adipocytes [16]. Platelets contain approximately 90% of PAI-1.

Structural peculiarities of PAI-1. The gene of human PAI-1 is localized on chromosome 7 in the region q 21.3-q 22 [17]. It contains 9 exons and 8 introns. Higher primates have two different transcripts of PAI-1 m-RNA: 2.6 and 3.6 kb. However, the translation products are the proteins of the same size [18]. The transcription and translation of platelet PAI-1 occur in megakaryocytes. However, megakaryocytes contain a considerable amount of PAI-1 m-RNA, which biosynthesis goes on at the platelet stage [19].

The PAI-1 gene transcription is regulated by a large number of hormones, cytokines, and growth factors [16, 20, 21]. The induction of PAI-1 expression by glucocorticoid hormones is of special interest, as PAI-1 was discovered as a dexamethasone-induced fibrinolytic inhibitor [22].

PAI-1 is synthesized as a precursor containing 402 amino acid residues (Fig. 1). During protein globule formation the signal peptide of 21 or 23 residues is cleaved from the molecule. So, the mature protein contains 379 or 381 amino acid residues [23, 24]. PAI-1 has 3 potential glycosylation sites at Asn 232, Asn 288, and Asn 352 [25]. The glycosylation PAI-1 depends on its origin in human organism.

It was shown that PAI-1, purified from plasma or platelets of healthy donors, had no glycans, meanwhile PAI-1 from endothelial cells or adipose tissue was glycosylated. It led to the conclusion, that the main source of PAI-1 in plasma of healthy people could be platelets but not endothelial cells [26]. The recent investigations have shown the importance of glycosylation for the functional activity of PAI-1. The glycosylated form of PAI-1 was found to possess a higher inhibitor activity [27].

Interaction of PAI-1 with vitronectin. The binding of vitronectin is very important for PAI-1 functioning [13, 28]. Vitronectin is found in plasma in a concentration of 2-4µM, mainly in a monomeric conformation, however, it has multimeric form in extracellular matrix [29]. PAI-1 is present in α-granules of platelets as a complex with vitronectin [30-32]. Using the methods of electron microscopy [33] and FITC-labeled proteins in flow cytometry [34]
it was shown that after platelets activation and releasing from α-granules the above-mentioned complex stays on the surface of activated platelets. The sites of vitronectin binding to PAI-1 were determined [35, 36] (see Fig.1). The method of site-directed mutagenesis showed that the most important residues in PAI-1 structure, which provide interaction with vitronectin, were Phe 132, Met 133, Leu 139 and Gly 146 [37].

On the other hand, the somatomedin-like domain (SMB) of vitronectin, containing 44 amino acid residues, is in charge of PAI-1 binding [34]. It is followed by the RGD sequence, which is known as an integrin-binding site. It was shown that vitronectin can bind C-terminal part of vimentin, which is exposed on the membrane of activated platelets [34].

During the experiments with immobilized proteins it was established that Kd value for binding immobilized vitronectin to PAI-1 was 1.9×10⁻⁷, however, if PAI-1 was immobilized, its Kd value for vitronectin binding was 5. 5×10⁻⁸. So, it was made a conclusion, that in vitronectin molecule there are at least two sites of PAI-1 binding, and one of these sites, which has higher affinity, becomes unapproachable after immobilization [38, 39]. The site of PAI-1 binding on the vitronectin molecule is different from integrin-binding site RGD. However, PAI-1 binding in the region of SMB domain can inhibit cell adhesion induced by integrins, possibly due to physical barrier [40, 41].

**PAI-1 latency transition.** PAI-1 can be found in active S (stressed) or latent R (relaxed) state [42]. It is known, that this protein is synthesized in an active configuration but spontaneously can convert to thermodynamically more stable latent form [43]. Reported half-life of the active PAI-1 is approximately 1-2 hours at 37°C and pH 7.4. However, this time can be decreased under conditions of low temperature and pH [44, 45]. In plasma the active PAI-1 is stabilized by its binding with vitronectin. The Kd value for binding of vitronectin to the active PAI-1 is 80 nM, while the latent PAI-1 binds with at least 200-fold lower affinity [46]. PAI-1 can be reactivated in vitro by treatment with denaturants such as SDS, guanidine HCl, and urea [43]. It has been suggested that negatively charged phospholipids exposed on the surface of activated platelets could reactivate PAI-1 [47].

Studying the latency transition of PAI-1 the researchers showed that this process was related with the changes in tertiary structure. This transition is one of the largest structural rearrangements known for a folded protein without a concomitant change in covalent structure. It was shown that some mutations could decrease the rate of latency transition [48]. So, the methods of site-directed mutagenesis are successfully used to study PAI-1 conformation transition.

To consider the mechanism of PAI-1 stressed-to-relaxed transition we should pay attention to the peculiarities of secondary and tertiary structures of this protein. There are 9 parts of alpha-helical structures marked as hA-hI and the strands of beta-sheet structure form beta-sheets A, B, and C. As it is shown at Fig. 2 beta-sheet A contains 6 strands (s1A-s6A) and beta-sheet C has 4 strands (s1C-s4C). There is a flexible site between beta sheets A and C. It contains 17 amino acid residues that is a site of recognition by serine proteases, so called central reactive loop (CRL). In the structure of CRL there is a special site P₁-P'₁, which is attacked by proteases. In case of PAI-1 this is a peptide bond Arg 369-Met 370 [49].

During S-R transition the N-terminal part of CRL inserts into beta-sheet A as s4A (see Fig.2, black arrow), and its C-terminal extension, forming s1C in the active conformer, stretched out along the surface of the molecule. As the P₁-P₁' is not cleaved during latency transition, the intact CRL must be stretched out and completely extracted from beta-sheet A and pass a narrow gate region between s3C and s4C. As a result s4A can be completed [50]. The rate of S-R for PAI-1 was suggested to be limited by the rate of CRL passage through the above mentioned gate region. This suggestion is in concordance with the data, obtained when basic amino acid residues in the loop s3C/s4C were substituted with acidic ones. Such substitution leads to the acceleration of latency transition [51]. Amino acid residues in the s1C region are also very important for the PAI-1 transition into latent state. It was shown that mutations, which led to weakness of interactions in this region, facilitated the conformational transition to the latent state and affected the overall structural stability of PAI-1 [52].

The presence of halide ions makes essential influence on latency transition. Crystallographic
analysis of a stable mutant form of active PAI-1 identified an anion-binding site between the central beta-sheet, where CRL was inserted, and the small surface domain. The anion insertion stabilized the active form of PAI-1. The stabilization induced by halide-anion was decreased in a row: F > Cl > Br >> I [53].

The binding of vitronectin to PAI-1 also influences the S-R transition. Half-life of the PAI-1 active form significantly increases in the presence of vitronectin [13, 28]. Some authors suggested that vitronectin induced conformational changes in CRL [54, 55]. Later, studying a three-dimensional structure of PAI-1-somatomedin B complex, the researchers made a conclusion that vitronectin sterically impedes the transition of s2A and s3A towards hE helical structure. So, the opening of beta-sheet A, which is important for CRL insertion, can be delayed. It is known that CRL insertion as s4A strand, which takes place during the PAI-1 latency transition, is accompanied with the transition of s1A, s2A, s3A, hF and the linking region binding hF and s3A. There are also some changes in the flexible linking region, which is close to the helical structures hE and hD. However, the data, obtained with the substitution of Lys 346 in s5A strand, suggested more complicated mechanism of vitronectin participation. It was shown that changing this lysine residue with alanine in PAI-1 structure in the absence of vitronectin delayed latency transition meanwhile in the presence of vitronectin such substitution led to the acceleration of this process [57]. It is obvious that vitronectin not only makes sterical effect but also leads to the conformational changes in PAI-1 structure. It is in concordance with the data of Sui G. S. et al [58]. They showed that significant acceleration of latency transition induced by point mutation in s1A and hF in PAI-1 protein was not observed in the presence of vitronectin.

There is another proposed mechanism concerning the PAI-1 transition into latent state and the role of vitronectin during this process [59]. According to the proposed model, there are some conformation states of PAI-1 (I-IV), which are determined by reciprocal location of s3A and s5A in A-sheet. State I: s3A and s5A are situated close to each other along their whole length. In this state CRL can not be inserted into sheet A. State II: s3A and s5A widen out near CRL, so the loop can be inserted into sheet A for a short distance. State III: CRL is inserted into sheet A till the P11 residue. State IV (latent state): CRL is completely inserted into sheet A. This state is practically irreversible under physiological conditions. The authors of this work suppose that in the presence of vitronectin the equilibrium between states II and III is shifted towards state II. As a result the latency transition of PAI-1 can be delayed.

Inhibitory mechanism of PAI-1. The inhibitory mechanism of PAI-1 was described in the literature, however, some details of this mechanism were not clarified [60]. Using modern biophysical and biochemical methods e.g. X-ray analysis, the main steps of the inhibition have been studied. The postulated mechanism suggests the following: 1) formation of a reversible Michaelis complex, where P1-P1' bond in CRL docks into the active site of serine protease; 2) splitting peptide bond P1-P1' and formation of an acyl-enzyme intermediate, in which the serine in active site of the protease is attached to the carbonyl group of Arg residue, which is located at P1 of the serpin molecule; 3) insertion of the N-terminal side of CRL into beta-sheet A, due to that the dragging of the protease to the other pole of serpin takes place; 4) deformation of the protease active site, preventing completion of the catalytic cycle [9, 61, 62]. UPA and TPA attack peptide bond Arg 369-Met 370 in PAI-1 molecule [63-66]. The substitution of these residues by the method of site-directed mutagenesis showed the importance of this peptide bond for the active centre of
TPA molecule. After splitting this bond, Arg 369 of PAI-1 and serine of the protease active centre form the ester bond. The existence of such bond was proved by direct methods of the protein chemistry [67]. In PAI-1 molecule amino acid residues Glu 373 and Glu 374 are very important for this reaction. They are complementary to the certain sites in 37-th loop of UPA and TPA, Arg 179-Arg 182 and Lys 296-Arg 304, correspondingly [68, 69]. The second order rate constants for the inhibition reaction are $10^7 \text{M}^{-1}\text{c}^{-1}$ and $10^6 \text{M}^{-1}\text{c}^{-1}$ for TPA and UPA, respectively [70].

Depending on the conditions, some stages of PAI-1 inhibition reaction are probably reversible. So, the covalent complex PAI-1-TPA (M.m. 110kDa), which is rather stable under physiological conditions, can be accomplished with NH$_2$OH [71] or SDS [72]. In circulating plasma PAI-1 can be present in three states: active state in a complex with vitronectin, inactive state as a complex PAI-1-vitronectin-TPA and free state [73-75]. The last one is also called split form. According to the proposed mechanism there are two alternative pathways of the protease-serpin reaction. The covalent acyl-enzyme intermediate can go either of two paths: 1) leading to the stable serpin-protease complex formation or 2) disintegration of intermediate complex with the formation of reactive centre-cleaved serpin and active protease. The equilibrium of these processes depends on temperature, ionic strength, detergents [76-78].

Under physiological conditions the PAI-1-protease complex can probably circulate in plasma till the moment when it is bound to the low density lipoprotein receptor 1B (LRP1B) of hepatocytes. After binding with this receptor, the complex PAI-1-TPA enters into the cell by phagocytosis and degrades under action of intracellular proteases [79].

Being the inhibitor of serine proteases, PAI-1 is able to inhibit not only TPA and UPA, but also the activated protein C and thrombin, however, for these proteins there are specific inhibitors in plasma (protein C inhibitor and antithrombin III). It is thought that the activated protein C binding with PAI-1 shows its pro-fibrinolytic activity. The second rate constant for the activated protein C inhibition by PAI-1 is $10^7 \text{M}^{-1}\text{c}^{-1}$ [80,81] In the presence of vitronectin this value was $1.8 \times 10^8 \text{M}^{-1}\text{c}^{-1}$ [82]. Noteworthy that under similar conditions the rate of the reaction between PAI-1 and TPA was 100 times higher, so protein C can affect the TPA activation only being in concentration excess [70, 82]. The activated protein C forms stable complexes with PAI-1 which can be eliminated from plasma by endothelial cells [43].

**PAI-1 as a modulator of cell adhesion in tumor cells.** Plasminogen, PAI-1, urokinase, and its specific receptor UPAR take part in the mitogenic, chemotactic, adhesive and migratory processes in cells. These components of fibrinolytic system play an important role in the neovascularization and tumor development [83]. It was shown that tumor tissues express urokinase and UPAR because these molecules provide tumor cells with proteolytic activity, which is a precondition for invasion [84, 85].

UPAR consists of three structural domains: D1, D2 and D3. The N-terminal domain, which is called D1, has a sequence responsible for urokinase binding, whereas D2 is needed for interaction with vitronectin [85]. In vitronectin molecule the SMB domain contains site for UPAR binding [85]. Urokinase binding with its specific receptor increases the UPAR affinity towards vitronectin and leads to the formation of stable complex between UPAR and some integrins (e.g. $\beta 1$ and $\beta 3$ integrins) [86], and induces activation of signal molecules, which are essential for the cell migration [84, 85].

It was found that the increase in urokinase level was accompanied by the elevation of PAI-1 concentration in plasma. That effect was observed for many types of tumor. Some authors showed that PAI-1 prevented cellular adhesion mediated by integrins and UPAR [84, 85, 87]. The adhesion inhibition by PAI-1 was observed for U937 cells (adhesion is provided by UPAR binding with vitronectin), MCF7 cells (make adhesive contact with vitronectin through integrins), HT1080 and HeLa (they use both adhesive receptors) [85]. The binding sites for PAI-1, UPAR and integrins are closely situated at the N-terminal part of vitronectin molecule. So PAI-1 can be considered as a possible competitor inhibitor in the interaction of UPAR or integrins with vitronectin [36, 85]. It was shown that the inhibition of adhesive process depends on the binding of the inhibitor to the SMB domain of vitronectin [88]. As a result PAI-1 is able to be in the
way of adhesive contacts, which are mediated by integrins, thus promoting cell migration (see Fig. 3). Besides, the components of fibrinolytic system take part in the neovascularization process of tumor cells. Urokinase and plasmin can contribute to angiogenesis by degrading the components of extracellular matrix and taking part into migration of endothelial cells. At the same time proteolysis induced by plasmin is controlled by physiological inhibitors such as PAI-1 to stabilize matrix and to group endotheliocytes during the vessel formation [85]. Angiogenic effect of PAI-1 depends on its concentration, tumor type and stage. PAI-1 deficiency has no effect on sarcoma development, melanoma metastasis, primary tumor growth and tumor extension in the model of adenocarcinoma of mammary glands [2]. PAI-1 deficiency prevents tumor invasion and vascularization. However, invasion and angiogenesis are restored if PAI-1 deficiency compensated and expression renewed. So, PAI-1 can contribute to the invasion and vascularization of tumor cells [88]. Recent researches have shown that a role of PAI-1 in cell migration is ambiguous and depends on its interaction with vitronectin. If PAI-1 forms a complex with vitronectin, the signaling and cell migration are suppressed [89]. These data are in accordance with the fact that PAI-1 prevents cell migration, which is induced by UPAR [90]. On the other hand, as it was mentioned above, PAI-1 competes for vitronectin binding site on the cellular surface, impedes cellular adhesion, which is mediated by integrins, and promotes cell migration. Apparently, the cell migration process depends not only on PAI-1 concentration but also on the type of its active form (vitronectin-bound or non-bound).

**Perspectives of PAI-1 investigations.** The inhibitors of serine proteases are very attractive for investigators because of their wide spread occurrence in nature. They are found in all living systems except bacteria [9]. In general, serpins control proteolytic degradation, but, as it was shown in case of PAI-1, their biological functions can be more complicated. One of the promising approaches to the serpin usage is the synthesis of compounds which possess the same efficiency as the natural inhibitors, but have their CRLs in constantly active state. These compounds could be used to inactivate the proteases of pathogenic microorganisms.

If the amount or activity of PAI-1 could be regulated we would be able to control the cellular adhesive properties and mobility which has a great importance for therapy [83]. Some authors consider PAI-1 as a potential target in tumor diseases [54, 55], therefore, the screening of agents inactivating PAI-1 is an important part of the modern investigations. Some peptides or monoclonal antibodies may be possible candidates. These agents of directed action have to be tested first on animal models, and in future they could be a base for creating medical preparations.

Д. Д. Жерносеков, Э. И. Золотарева, А. С. Кондратюк

Структурно-функциональные особенности ингибитора актива- тора плаэминогена ПАИ-1

Резюме

ПАИ-1, важный компонент системы гемостаза, является специфи- ческим ингибитором активатора плаэминогена тканевого (ТПА) и урокиназного (УПА) типов. ПАИ-1 относится к семейству серпинов. Взаимодействие с соматомедицинобб- ным доменом урокиназина стабилизирует активную форму ингибитора. Переход ПАИ-1 в латентное состояние связан с конформационными изменениями в области петли реактив- ного центра. Механизм ингибиторного действия ПАИ-1 соот- ветствует классической схеме ингибитирования серпинами. ПАИ-1 блокирует адгезию, опосредованную рецептором УПА и интегринами, выполняя при этом важную роль в адгезивных процессах и ангиогенезе. Изменения уровня ПАИ-1 рассматриваются как важный прогностический признак при заболеваниях
REFERENCES


42. Sancho E., Declerck P. J., Price N. C., Kelly S. M., Booth N. A. Conformational studies on plasminogen activator inhibitor (PAI-1) in active, latent, substrate, and cleaved forms // Biochemistry.—1995.–34, N 3.– P. 1064–1069.
44. Levin E. G., Santell L. Conversion of the active to latent plasminogen activator inhibitor from human endothelial cells // Blood.—1987.–70, N 4.– P. 1090–1098.


62. Wind T., Hanssen M., Jensen J. K., Andreasen P. A. The molecular basis for anti-protelytic and non-protelytic functions of plasminogen activator inhibitor type-1: roles of the reactive centre loop, the shudder region, the flexible joint region and the small serpin fragment // J. Biol. Chem.–2002.–287, N 1.–P. 21–36.


